SCM
QTTB icon

Sterling Capital Management’s Q32 Bio QTTB Stock Holding History

Sterling Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105
Closed -$173 – 3424
2025
Q1 		$173 Sell
105
-100
-49% -$269 ﹤0.01% 3102
2024
Q4 		$705 Buy
205
+186
+979% +$5.87K ﹤0.01% 2993
2024
Q3 		$848 Buy
+19
New +$698 ﹤0.01% 2625

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sterling Capital Management's QTTB Position: Q2 2025 in Review

Sterling Capital Management sold out of Q32 Bio (QTTB) in Q2 2025, closing a stake of 105 shares — an estimated $173 sold.

Sterling Capital Management first reported a position in QTTB in Q3 2024 and held it in 3 quarters. The position peaked at $848 in Q3 2024. 61 funds tracked by Wall St. Rank hold QTTB as of Q2 2025.

  • Sterling Capital Management reported no remaining Q32 Bio position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 105 Q32 Bio shares in Q2 2025, an estimated $173.
  • Sterling Capital Management first reported a position in Q32 Bio in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Q32 Bio position peaked at $848 in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.